证券代码：301235 证券简称：华康医疗 公告编号：2023-044 武汉华康世纪医疗股份有限公司 关于举办2022年度网上业绩说明会的公告 武汉华康世纪医疗股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为 便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 15 日（星期一）15:00-17:00 在"价值在线"（www.ir-online.cn） 举办公司 2022 年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投资 者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 05 月 15 日（星期一）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 出席本次年度网上业绩说明会的人员有：董事长谭平涛先生，总经理谢新强 先生，独立董事郭孟焕女士，董事会秘书、副总经理彭沾先生，财务负责人张英 超女士，保荐代表人李鹏程先生。 三、投资者参加方式 投资者可于 2023 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 240,206,327.57, representing an increase of 82.92% compared to CNY 131,319,672.55 in the same period last year[4]. - The net loss attributable to shareholders for Q1 2023 was CNY -17,309,522.74, a decrease of 101.66% from CNY -8,583,730.95 in Q1 2022[4]. - Net profit for Q1 2023 is -17,309,522.74 RMB, a decrease of 101.66% compared to Q1 2022[14]. - The basic and diluted earnings per share were both -¥0.16, worsening from -¥0.09 in the previous period[28]. - Total operating revenue for the current period reached ¥240,206,327.57, a significant increase from ¥131,319,672.55 in the previous period, representing an increase of approximately 83%[26]. - The net loss for the current period was ¥17,309,522.74, compared to a net loss of ¥8,583,730.95 in the previous period, reflecting an increase in losses of approximately 102%[28]. Cash Flow - The net cash flow from operating activities was CNY -205,749,592.42, a decline of 6.47% compared to CNY -193,250,545.06 in the previous year[4]. - Cash flow from operating activities showed a net outflow of ¥205,749,592.42, compared to a net outflow of ¥193,250,545.06 in the previous period[30]. - Investment activities generated a net cash flow of 404,394,431.90 RMB, a 178.15% increase from the previous year[15]. - Cash flow from investing activities generated a net inflow of ¥404,394,431.90, contrasting with a net outflow of ¥517,453,534.57 in the previous period[30]. - Financing activities resulted in a net cash flow of 97,149,635.24 RMB, down 88.25% from the previous year[15]. - Cash flow from financing activities resulted in a net inflow of ¥97,149,635.24, down from ¥826,578,481.17 in the previous period[32]. - The ending cash and cash equivalents balance was ¥429,125,286.77, an increase from ¥305,091,543.28 in the previous period[32]. - The company's cash and cash equivalents increased by 120.10% to CNY 555,284,119.25, primarily due to the maturity of idle raised funds[11]. Assets and Liabilities - As of the end of Q1 2023, the company had a total asset value of CNY 2,319,324,309.61, a decrease of 2.14% from CNY 2,369,993,275.66 at the end of the previous year[4]. - The total current assets as of March 31, 2023, amounted to CNY 2,086,325,371.35, a decrease from CNY 2,133,466,006.70 at the beginning of the year[21]. - Total liabilities decreased to CNY 670,385,913.93 from CNY 717,195,126.15, a reduction of about 6.5%[23]. - The total assets as of March 31, 2023, were CNY 2,319,324,309.61, down from CNY 2,369,993,275.66 at the beginning of the year[23]. - The company's equity attributable to shareholders decreased to CNY 1,648,938,395.68 from CNY 1,652,798,149.51, a decline of approximately 0.2%[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,691[14]. - Major shareholder, Tan Pingtao, holds 44.23% of the shares, totaling 46,708,990 shares[14]. - Sun Life Insurance Company holds 6.50% of the shares, totaling 6,864,046 shares[14]. - The company has a total of 10 major shareholders, with varying percentages of ownership[16]. - The company has a total of 80,558,504 shares under lock-up agreements, with 25,312,294 shares released during the period[19]. Research and Development - Research and development expenses increased by 129.32% to CNY 23,300,468.90 compared to CNY 10,160,474.31 in Q1 2022[12]. - The company is focusing on R&D investments, which have increased during the reporting period[14]. - Research and development expenses for the current period were ¥23,300,468.90, significantly higher than ¥10,160,474.31 in the previous period, marking an increase of approximately 129%[26]. Operational Expenses - Operating expenses increased significantly, contributing to the net loss[14]. - Sales expenses rose by 40.04% to CNY 33,931,560.78, driven by an increase in sales personnel and marketing costs[12]. - Total operating costs amounted to ¥267,516,174.95, up from ¥146,259,169.33, indicating a rise of about 83%[26]. Future Outlook - The company plans to continue its market expansion and product development strategies in the upcoming quarters[22]. - The company reported a significant increase in cash flow, which will support future investments and operational needs[21].

Financial Performance - The company's operating revenue for 2022 was approximately ¥1.19 billion, representing a 38.12% increase compared to ¥860.81 million in 2021[32]. - The net profit attributable to shareholders for 2022 was approximately ¥102.49 million, a 25.97% increase from ¥81.36 million in 2021[32]. - The cash flow from operating activities showed a significant decline, with a net outflow of approximately ¥342.10 million in 2022 compared to a net inflow of ¥44.59 million in 2021, marking an 867.16% decrease[32]. - The total assets at the end of 2022 reached approximately ¥2.37 billion, a 91.32% increase from ¥1.24 billion at the end of 2021[32]. - The company's net assets attributable to shareholders increased by 179.16% to approximately ¥1.65 billion at the end of 2022, up from ¥592.06 million at the end of 2021[32]. - The basic earnings per share for 2022 was ¥0.99, a decrease of 3.88% from ¥1.03 in 2021[32]. - The company reported a weighted average return on equity of 6.76% for 2022, down from 14.76% in 2021, indicating a decline of 8.00%[32]. - The company achieved a revenue of 1.1889 billion yuan in 2022, representing a year-on-year growth of 38.12%[60]. - The net profit attributable to shareholders for 2022 was 102.49 million yuan, a 25.97% increase compared to the previous year[60]. - The company's total assets grew by 91.32% to 2,369.99 million yuan by the end of the reporting period[60]. Cash Flow and Investments - The net cash flow from operating activities decreased by 867.16% year-on-year, primarily due to increased inventory and accounts receivable amid economic downturn and business expansion[115]. - The net cash flow from investment activities decreased by 7,003.49% year-on-year, mainly due to the use of idle raised funds for purchasing financial products and construction of investment projects[116]. - The net cash flow from financing activities increased by 1,323.19% year-on-year, primarily due to funds received from the IPO[117]. - Total cash inflow from operating activities was 844.72 million yuan, while total cash outflow was 1,186.81 million yuan, resulting in a net cash outflow of 342.10 million yuan[115]. - The company's total assets included cash and cash equivalents of 252.29 million yuan, accounting for 10.65% of total assets, a decrease of 8.37% from the previous year[121]. - The company raised a total of RMB 103,752.00 million through the issuance of 26.4 million shares at RMB 39.30 per share, with a net amount of RMB 94,950.28 million after deducting issuance costs of RMB 8,801.72 million[133]. - As of December 31, 2022, the company has utilized RMB 39,542.50 million of the raised funds, leaving a balance of RMB 55,407.78 million in unutilized funds[134]. Market and Business Expansion - The company plans to continue expanding its market presence and developing new technologies in the medical purification system sector[42]. - The company is focused on expanding its market presence and enhancing its product offerings through research and development[128]. - The company is exploring new strategies for market expansion and potential mergers and acquisitions to strengthen its competitive position[154]. - The company is actively investing in R&D for new technologies, with a budget allocation of approximately $10 million for the next year[158]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next fiscal year[156]. - The overall market expansion strategy includes entering three new regional markets by the end of the fiscal year[156]. Research and Development - The company has developed a range of patented technologies and integrated information systems to enhance its market competitiveness[7]. - The company has 4 invention patents and 141 utility model patents as of December 31, 2022, showcasing its strong R&D capabilities[94]. - The company completed several key R&D projects, including an intelligent gas system and a remote alarm control system, enhancing its competitive edge in the medical industry[113]. - The company aims to enhance its industry reputation and competitiveness through innovative R&D initiatives and strategic expansions[113]. - The number of R&D personnel increased by 44.74% from 152 in 2021 to 220 in 2022, indicating a significant expansion in the R&D team[114]. Corporate Governance - The company is committed to enhancing its governance level through regular reviews and approvals of major decisions by the board and shareholders[169]. - The company maintains independence from its controlling shareholders, ensuring that its operations and decision-making processes are not influenced by external entities[164]. - The board of directors is supported by specialized committees to enhance decision-making efficiency and professionalism[165]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with investors[167]. - The company is actively engaging in corporate governance practices to ensure compliance and transparency[182]. Operational Efficiency - The company emphasizes cost management throughout the bidding and project execution phases, effectively reducing operational cost risks[84]. - The company is focused on improving the quality of medical services through the establishment of specialized medical institutions and diagnostic centers[46]. - The company is committed to improving its corporate image and operational management to support its rapid development and technological advancements[151]. - The company aims to improve project management efficiency and profitability through refined management practices and strict quality control measures[149]. Strategic Partnerships and Collaborations - The company has formed strategic partnerships with renowned design institutes, increasing its market influence and order quality[88]. - The company is committed to fostering international cooperation in technology innovation and resource sharing in the healthcare sector[43]. - The company is encouraged to strengthen cooperation with national laboratories and research institutions to enhance innovation in the biomedicine field[45]. Social Responsibility and Community Engagement - The company actively fulfills its corporate social responsibility, balancing the interests of shareholders, employees, and society to promote sustainable development[168]. - The company aims to enhance the infrastructure of medical institutions, focusing on building national and regional medical centers, particularly in under-resourced areas[43].

编号：2022-014 证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 动类别 | 特定对象调研 □媒体采访 □新闻发布会 现场参观 | 分析师会议 业绩说明会 路演活动 | | 参与单 ...

编号：2022-010 证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

编号：2022-007 证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投 资 者 关 系活 动类别 | 特定对象调研 □媒体采访 □新闻发布会 □现场参观 | 分析师会议 业绩说明会 □路演活动 | | 参 与 单 位 名称 及人员姓名 | 其他（网络） 线上参与 2022 2021 | 年湖北辖区上市公司投资 ...

编号：2022-006 证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------------------|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投 资 者 关系 活 动类别 | 特定对象调研 □媒 ...

编号：2022-005 证券代码：301235 证券简称：华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301235 证券简称：华康医疗 编号：2022-011 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 动类别 | 特定对象调研 □媒体采访 □新闻发布会 现场 ...